A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions
Sponsor: Krystal Biotech, Inc.
A PHASE1 clinical study on Fine Lines and Skin Roughness, this trial is ongoing. The trial is conducted by Krystal Biotech, Inc. and has accumulated 10 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Jun 2025 — Present [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Jun 2025 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE1
-
Feb 2024 — May 2024 [monthly]
Recruiting PHASE1
▶ Show 5 earlier versions
-
May 2023 — Feb 2024 [monthly]
Recruiting PHASE1
Status: Active Not Recruiting → Recruiting
-
Jan 2023 — May 2023 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Sep 2021 — Jan 2023 [monthly]
Recruiting PHASE1
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE1
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Krystal Biotech, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .